Fertility Germline Testing denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for fertility germline testing are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Fertility-Related Germline Testing as Experimental

Cigna's experimental or investigational denial for germline genetic testing in a fertility context means their medical policy has determined that the specific testing methodology or clinical application requested does not yet meet their threshold for established clinical utility — or that the particular test panel or indication falls outside their current coverage criteria.

This denial type is specifically eligible for independent external review under federal law and is frequently overturned when the ordering provider documents that the test is supported by professional society guidelines and peer-reviewed evidence.

## Why This Denial Is Commonly Appealed Successfully

Germline testing technologies in reproductive medicine have advanced rapidly, and insurer coverage policies sometimes lag behind professional society recommendations from organizations such as the American College of Medical Genetics (ACMG), the American Society for Reproductive Medicine (ASRM), or the American College of Obstetricians and Gynecologists (ACOG). An IRO reviewing an experimental denial will assess whether the test is consistent with generally accepted standards of medical practice — not just a single insurer's policy.

## Federal Appeal Rights

• ACA §2719 external review: experimental/investigational denials are specifically subject to independent external review. This is one of the most important protections for this denial type. An accredited IRO evaluates whether the denial aligns with generally accepted standards of care.
• ERISA §503: employer-plan members have full-and-fair internal review rights before external review.
• You generally have approximately four months from the denial date to request external review.
• Expedited review: if the testing is time-sensitive due to active fertility treatment cycles, reproductive age considerations, or an underlying diagnosis requiring urgent clinical action, your physician should document this and request expedited review.

## Concrete Appeal Timeline

1. Request a copy of the Cigna coverage policy or medical policy cited in the denial. 2. Have your ordering provider (reproductive endocrinologist, genetic counselor, or oncologist) prepare a letter citing professional society guideline support. 3. File the internal appeal. 4. If upheld, file for IRO external review immediately — do not wait.

## Documentation to Gather

• Clinical indication: complete records establishing the specific medical or reproductive reason the test was ordered (e.g., family history of hereditary condition, known pathogenic variant in a partner, personal cancer history, fertility treatment plan).
• Professional society guideline support: your ordering provider's letter should reference the relevant guideline organizations (ACMG, ASRM, ACOG, Society of Gynecologic Oncology as applicable) and describe how this test fits within their recommendations for your clinical situation.
• Peer-reviewed literature support: your genetic counselor or physician may cite the basis for clinical utility in your specific context.
• Reproductive timeline documentation: if you are in an active assisted-reproduction cycle, document the timeline and why delay is clinically significant.
• Prior genetic counseling notes: a genetic counselor's pre-test assessment of clinical utility and appropriateness strengthens the appeal substantially.

## Criteria-Mapping Structure

Obtain Cigna's current coverage policy for the specific germline test and map each criterion:

| Cigna Experimental-Denial Criterion | Your Rebuttal Evidence | |---|---| | Lacks established clinical utility | [Cite applicable guideline organization recommendation + clinical rationale letter] | | Not supported by adequate evidence | [Genetic counselor's letter citing applicable professional society guidance] | | Indication not covered under policy | [Map your clinical indication to policy coverage categories; cite state law if applicable] |

Verify the exact language in Cigna's current medical coverage policy for germline genetic testing and for fertility-related genetic services. Confirm that the applicable professional society guidelines your provider cites are current (these organizations update their guidelines regularly). Time-sensitive reproductive circumstances are a legitimate basis to request expedited processing at every stage.